Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 17, 2021

SELL
$207.02 - $241.31 $284,652 - $331,801
-1,375 Closed
0 $0
Q4 2020

Feb 26, 2021

BUY
$207.01 - $276.09 $284,638 - $379,623
1,375 New
1,375 $325,000
Q2 2019

Aug 14, 2019

SELL
$164.61 - $190.37 $378,603 - $437,851
-2,300 Closed
0 $0
Q1 2019

May 14, 2019

BUY
$163.73 - $194.7 $376,579 - $447,810
2,300 New
2,300 $423,000
Q4 2018

Feb 13, 2019

BUY
$151.91 - $192.21 $18,988 - $24,026
125 Added 3.14%
4,100 $679,000
Q3 2018

Nov 14, 2018

SELL
$167.73 - $192.74 $570,282 - $655,316
-3,400 Closed
0 $0
Q2 2018

Aug 10, 2018

BUY
$145.72 - $169.96 $495,448 - $577,864
3,400 New
3,400 $578,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $117B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Doheny Asset Management /Ca Portfolio

Follow Doheny Asset Management /Ca and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Doheny Asset Management /Ca, based on Form 13F filings with the SEC.

News

Stay updated on Doheny Asset Management /Ca with notifications on news.